Inhibition of Notch has been shown to prevent upregulation of Notch ligands, e.g. DLL1, after radiotherapy in breast cancer cells, and the downregulation of DLL1 in the combination therapy group in the present study may indicate a possible explanation of the mechanism involved in the enhanced anti-tumor effects in this treatment group [52]. The gene discussed is DLL1; the disease is breast carcinoma.